Skip to main content

Birch Pollen Allergy

6
Pipeline Programs
2
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
3 programs
1
2
Recombinant birch pollenPhase 31 trial
recombinant birch pollen allergen (rBet v1-FV)Phase 3
Recombinant birch pollenPhase 21 trial
Active Trials
NCT00266526CompletedEst. Jul 2005
NCT00309062CompletedEst. Jun 2009
Desentum
DesentumFinland - Espoo
3 programs
2
1
DM-101PXPhase 21 trial
DM-101Phase 11 trial
DM-101PXPhase 11 trial
Active Trials
NCT04266028Completed27Est. May 2021
NCT06037148Completed30Est. Mar 2024
NCT07254871Active Not Recruiting100Est. Aug 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AllergopharmaRecombinant birch pollen
DesentumDM-101PX
AllergopharmaRecombinant birch pollen
DesentumDM-101PX
DesentumDM-101

Clinical Trials (5)

Total enrollment: 157 patients across 5 trials

NCT00309062AllergopharmaRecombinant birch pollen

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Start: Dec 2003Est. completion: Jun 2009
Phase 3Completed
NCT07254871DesentumDM-101PX

Study of DM-101PX in Adults With Birch Pollen Allergy

Start: Sep 2025Est. completion: Aug 2026100 patients
Phase 2Active Not Recruiting
NCT00266526AllergopharmaRecombinant birch pollen

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Start: Jul 2003Est. completion: Jul 2005
Phase 2Completed
NCT06037148DesentumDM-101PX

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

Start: Sep 2023Est. completion: Mar 202430 patients
Phase 1Completed
NCT04266028DesentumDM-101

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Start: Feb 2020Est. completion: May 202127 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.